Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (NASDAQ:INSM) and Pacira Pharmaceuticals (NASDAQ:PCRX).
Insmed (INSM)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Insmed today and set a price target of $56. The company’s shares opened today at $20.85.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 31.4% and a 53.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Currently, the analyst consensus on Insmed is a Moderate Buy with an average price target of $41.50, implying a 99.0% upside from current levels. In a report issued on September 18, H.C. Wainwright also maintained a Buy rating on the stock with a $43 price target.
.
See today’s analyst top recommended stocks >>
Pacira Pharmaceuticals (PCRX)
Mizuho Securities analyst Irina Rivkind Koffler reiterated a Hold rating on Pacira Pharmaceuticals today and set a price target of $43. The company’s shares opened today at $49.05, close to its 52-week high of $52.60.
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 10.6% and a 45.6% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $50.92.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
